Figure 1
Diabetic model. (A) Profile of in vivo experiments in the four groups of animals, two diabetic groups, one treated with capsaicin (Db + Cap) and another without the treatment (Db), and two non-diabetic control group, one without and another with capsaicin treatment (Ctrl and Ctrl + Cap). Timing of treatments with capsaicin (Cap), streptozotocin (STZ) and the solvent of capsaicin (veh) and STZ (Veh) is indicated by the arrows. (B) Chronic activation of TRPV1 by dietary capsaicin significantly inhibits the elevation of fasting blood glucose (FBG) at the end of the 8 weeks after the treatment with STZ. (C) Significant increases in food consumption in the first 7 days and in the following 7 weeks (D) were observed in the diabetic animals including the capsaicin treated diabetic animals (Cap indicates the start timing of the capsaicin treatment and STZ, the timing of injection of STZ). (E) The significant increases in drinking water in the first 7 days after the treatment of STZ (labeled as STZ) and in the following 7 weeks (F) in the diabetic animals including the capsaicin treated (Cap indicates the start timing of capsaicin treatment). (G) The serum insulin was significantly lower in the diabetic and capsaicin treated diabetic animals, at the end of the 8 weeks after injection of STZ. (H) Significantly lower body weights were detected in the diabetic animals, with and without the capsaicin treatment and in the non-diabetic animals treated with capsaicin. Control or Ctrl non-diabetic control group, Ctrl + Cap non-diabetic animals treated with capsaicin, Diabetic diabetic group, Db + Cap diabetic animals treated with capsaicin. *p < 0.05, compared to the control; **p < 0.01, compared to the control; ##p < 0.01, compared to diabetic.
